Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients
03.04.2017Follicular lymphoma is an indolent yet incurable lymphoma characterized by a relapsingremitting course with initial responses to standard therapies, invariably followed by shorter disease free intervals. In recent years, significant treatment improve...
Klinische Forschung - 03.04.2017 - 30.09.2020
Automatisch geschlossen
Projektleitung: Hitz Felicitas
SAKK 41/16: Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal ca cer. A multicenter phase Ib trial (RECAP)
07.03.2017Despite treatment of locally advanced rectal cancer re-lapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS). Recent studies with...
Klinische Forschung - 07.03.2017 - 31.07.2019
Automatisch geschlossen
Projektleitung: Jörger Markus
Amyloidosis Registry
01.01.2017
Klinische Forschung - 01.01.2017 - 31.12.2030
Laufend
Projektleitung: Hitz Felicitas
Mitarbeiter/innen: Steiner Marianne
SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial
07.11.2016Advanced triple negative breast cancer (TNBC) is a highly chemosensitive disease displaying a dismal short-term prognosis with more than three quarters of patients in pro-gression 12 months after the initiation of conventional chemotherapy. Approxima...
Klinische Forschung - 07.11.2016 - 31.05.2023
Automatisch geschlossen
Projektleitung: Weder Patrik
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
01.11.2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Grundlagenforschung - 01.11.2016 - 31.10.2018
Automatisch geschlossen
Projektleitung: Driessen Christoph
Mitarbeiter/innen: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the to erability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients
27.10.2016This is a prospective, open label, multicenter study that is conducted in the frame of a masterprotocol with multiple parallel randomized phase II arms. The scheme of this design consists of one arm with the standard treatment for AML (the 10-day dec...
Klinische Forschung - 27.10.2016 - 31.07.2018
Automatisch geschlossen
Projektleitung: Fehr Martin
CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
21.10.2016CA209577 is a phase 3, randomized, double-blind, placebo controlled study of adjuvant nivolumab in subjects with resected esophageal cancer (EC), or gastroesophageal junction (GEJ) cancer who have received chemoradiother-apy(CRT) followed by surgery....
Klinische Forschung - 21.10.2016 - 30.11.2017
Automatisch geschlossen
Projektleitung: Weisshaupt Christian
PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
04.10.2016In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concen...
Klinische Forschung - 04.10.2016 - 27.02.2024
Abgeschlossen
Projektleitung: Jörger Markus
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451
07.09.2016This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy. Approximately 810...
Klinische Forschung - 07.09.2016 - 30.11.2020
Automatisch geschlossen
Projektleitung: Früh Martin
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
19.08.2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Klinische Forschung - 19.08.2016 - 31.01.2018
Automatisch geschlossen
Projektleitung: Jörger Markus
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata
27.07.2016This is a nonrandomized, multinational, open-label trial of pembrolizumab (MK-3475) in subjects with metastatic cas-tration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. The trial will be conducted in conform...
Klinische Forschung - 27.07.2016 - 30.06.2019
Automatisch geschlossen
Projektleitung: Omlin Aurelius
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti PD-1 Monoclonal Anti-body) in Advanced Solid Tumors
21.07.2016This is a Phase 1/2a, open-label study of BMS-986156 administered as a single agent and in combination with nivolumab in subjects with advanced solid tumors. The study will be conducted in 4 parts. Parts A and B will consist of dose escalation with B...
Klinische Forschung - 21.07.2016 - 30.09.2017
Automatisch geschlossen
Projektleitung: Jörger Markus
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
15.07.2016
Klinische Forschung - 15.07.2016 - 15.10.2019
Automatisch geschlossen
Projektleitung: Flatz Lukas
Mitarbeiter/innen: Diem Stefan
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA (Abi-RE)
12.06.2016Clinical Trial with an IMP, risk category B according to HRA. Abiraterone acetate (AA) is a standard treatment option both in chemotherapy naïve and docetaxel pre-treated men with metastatic castrate-resistant prostate cancer (CRPC). With the approva...
Klinische Forschung - 12.06.2016 - 31.12.2017
Automatisch geschlossen
Projektleitung: Omlin Aurelius
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
03.06.2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Klinische Forschung - 03.06.2016 - 31.05.2026
Laufend
Projektleitung: Silzle Tobias
Mitarbeiter/innen: Quinter Janine
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
27.05.2016Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of up to 42 days, eligible subjects can be randomized to either pembrolizumab (experimental...
Klinische Forschung - 27.05.2016 - 30.11.2020
Automatisch geschlossen
Projektleitung: Weisshaupt Christian
SAKK 08/14 Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalu-tamide vs. Enzalutamide alone (IMPROVE TRIAL)
20.05.2016The current standard of care for patients with metastatic castration resistant prostate cancer (mCRPC) and dis-ease progression is either treatment with abiraterone acetate and prednisone in asymptomatic or mildly symp-tomatic patients without viscer...
Klinische Forschung - 20.05.2016 - 31.07.2026
Laufend
Projektleitung: Rothermundt Christian
Klinische Phase-I-Studie zur Beurteilung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von EDO-S101, einem First-in-Class alkylierenden HDA-Ci-Fusionsmolekül, bei rezidivierenden/refraktären häma-tologischen Malignitäten
04.05.2016Es handelt sich um eine zweistufige Phase-I-Studie. Stufe 1 der Studie dient der Bestimmung der MTD, der Identifika-tion der empfohlenen Stufe-II-Dosierung sowie der Ermitt-lung der optimalen Infusionsdauer. Stufe 2 dient der Bestä-tigung der Sicherh...
Klinische Forschung - 04.05.2016 - 01.01.2018
Automatisch geschlossen
Projektleitung: Driessen Christoph
A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin Paclitaxel with or without bevacizumab compared with carboplatin Paclitaxel bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer
14.04.2016MPDL3280A ist ein humaner monoklonaler Antikörper der Immunglobulin (Ig)-Klasse G1 und wird in den Ovarialzellen des chinesischen Hamsters produziert. MPDL3280A wird als mögliche Therapie gegen solide Tumore und hämatologische Malignitäten in Mensche...
Klinische Forschung - 14.04.2016 - 14.04.2020
Automatisch geschlossen
Projektleitung: Früh Martin
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
30.03.2016Primary/co-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or with-out standard adjuvant chemotherapy for stage IB (T ≥ 4 cm) -II-IIIA NSCLC patien...
Klinische Forschung - 30.03.2016 - 30.03.2020
Automatisch geschlossen
Projektleitung: Früh Martin